Antagonism of glycerol trinitrate activity by an inhibitor of glutathione S-transferase

Biochemical Pharmacology
R A YeatesM Leitold

Abstract

The in vitro spasmolytic activity of glycerol trinitrate was measured on the KCl-contraction of aorta strips from the rabbit. In the presence of sulphobromophthalein, a known inhibitor of glutathione S-transferase, the dose-activity curve for the nitrate was displaced to the right. Much smaller displacements were obtained with the control spasmolytic substances--papaverine and S-nitroso-N-acetylpenicillamine. It was confirmed that sulphobromophthalein inhibits glutathione S-transferase activity in aorta homogenates. Aorta extracts did not detectably catalyze the reaction between glutathione and sulphobromophthalein and the glutathione level was not decreased by treating the intact aorta with sulphobromophthalein. It is concluded that sulphobromophthalein acts as a specific antagonist of the spasmolytic activity of glycerol trinitrate, probably as a result of its inhibition of glutathione S-transferase. It thus seems probable that glutathione and glutathione S-transferase are involved in the pharmacological activation of the organic nitrates.

References

Apr 23, 1985·European Journal of Pharmacology·C A Gruetter, S M Lemke
Sep 15, 1985·The Biochemical Journal·C GuthenbergB Mannervik
Jul 29, 1983·Biochemical and Biophysical Research Communications·S YalçinB Mannervik

❮ Previous
Next ❯

Citations

Oct 1, 1994·Cardiovascular Drugs and Therapy·K E Torfgård, J Ahlner
May 28, 1992·Biochemical Pharmacology·D T Lau, L Z Benet
Jan 4, 1994·European Journal of Pharmacology·N SatakeS Shibata
Jul 1, 1994·Trends in Pharmacological Sciences·B M BennettW C Simon
Dec 23, 1999·European Journal of Pharmacology·P AgvaldM G Persson
Oct 12, 2000·Nihon rinsho. Japanese journal of clinical medicine·Y SaitoR Nagai
Jun 1, 1997·Trends in Genetics : TIG·S SawcerA Compston
Feb 1, 1997·Nature Biotechnology·A GoelS K Dube
Jan 30, 2002·British Journal of Pharmacology·Per AgvaldLars E Gustafsson
Oct 23, 2002·Clinical and Experimental Pharmacology & Physiology·Toshihiro MatsuzakiMatao Sakanashi
Feb 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D SalveminiJ Vane
Jun 12, 2010·Cardiology in Review·Vaughn E NossamanPhilip J Kadowitz
Apr 1, 1994·Clinical and Experimental Pharmacology & Physiology·C G LiM J Rand
Nov 1, 1993·British Journal of Pharmacology·D SalveminiE Anggard
Apr 7, 2012·Critical Care Research and Practice·Bobby NossamanPhilip Kadowitz
Nov 2, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Julio C B Ferreira, Daria Mochly-Rosen
Jun 13, 2002·Proceedings of the National Academy of Sciences of the United States of America·Louis J Ignarro
Jun 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhiqiang ChenJonathan S Stamler
May 1, 1993·Circulation·D G Harrison, J N Bates
Oct 11, 2003·Circulation Research·Andrei L KleschyovThomas Münzel
Sep 9, 2009·Fundamental & Clinical Pharmacology·Magdalena DudekLidia Włodek
Feb 15, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Martin W HuellnerThomas Rau
Apr 11, 2002·Chemical Reviews·Peng George WangAdam J Janczuk
Jul 7, 2000·Pharmacology & Therapeutics·T KomaruK Shirato
Aug 1, 1993·Japanese Journal of Pharmacology·M IshikawaK Sasaki
Jun 1, 1996·Japanese Journal of Pharmacology·Y AniyaM Sakanashi
Jul 12, 2008·European Journal of Pharmacology·Magdalena DudekLidia Włodek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.